New Partnership May Expand Use of Prostate Cancer AI Technology Platform

"The AI model has achieved high prediction accuracy and outperformed some of the currently used markers in both Caucasian and African American patient cohorts for a much-improved patient outcome," according to Ash Tewari, MD, MBBS, MCh, FRCS.

Developer Myriad Genetics has formed a strategic partnership with PATHOMIQ to exclusively license the artificial intelligence (AI) technology platform PATHOMIQ_PRAD for prostate cancer prognosis in the US, according to a press release from Myriad Genetics.¹

According to the press release, use of the AI platform may allow urologists and radiation oncologists to make informed treatment decisions before therapy at the time of biopsy for active surveillance and after surgery or radiotherapy. The platform is designed to decode hidden information from complex morphological structures across cancer pathology landscapes, which may help predict patient outcomes, treatment responses, and genotype mutations. Additionally, the technology may supply results within 1 to 2 days following receipt of digital images from a patient’s sample.

“I am excited to have co-developed, with the PATHOMIQ team, the PATHOMIQ-PRAD AI model for prostate cancer treatment response prediction and identification of [patients with] high-risk prostate cancer who will experience early metastasis post-radical prostatectomy,” Ash Tewari, MD, MBBS, MCh, FRCS, professor and chair of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, stated in the press release.¹ “The AI model has achieved high prediction accuracy and outperformed some of the currently used markers in both Caucasian and African American patient cohorts for a much-improved patient outcome.”

Findings that validate the use of PATHOMIQ_PRAD for precisely risk stratifying prostate cancer progression in patients with clinical intermediate risk were previously published in European Urology.² Investigators assessed 176 patients with intermediate-risk prostate cancer who received radical prostatectomy at the Icahn School of Medicine at Mount Sinai without any subsequent adjuvant therapy. Overall, 78 patients experienced biochemical recurrence (BCR), and 41 developed metastases.

Based on univariate analysis, investigators highlighted that PATHOMIQ_PRAD identified those who were at a high risk of BCR (HR, 4.347; P <.0001) and metastasis (HR, 4.656; P <.0005). Additionally, decision curve analysis for 3-year and 5-year likelihood of BCR and 5-year probability of metastasis indicated that PATHOMIQ_PRAD yielded a superior net benefit compared with existing nomograms such as CAPRA-S and genomic scores.

“In summary, PATHOMIQ_PRAD demonstrates superior clinical utility in predicting the risk of BCR and metastasis, and significantly improves risk stratification for intermediate-risk [prostate cancer], and could potentially impact patient management, personalized therapy, biomarker discovery, and patient selection for clinical trial of novel therapies,” Sujit S. Nair, PhD, director of GU Immunotherapy Research in the Department of Urology at Icahn School of Medicine at Mount Sinai, wrote with study coauthors.²

The press release noted that the strategic collaboration may complement prior offerings of combined germline and comprehensive tumor profiling recommended in NCCN guidelines for prostate cancer management. In December 2024, developers announced that Prolaris, a molecular diagnostic test designed to supply personalized information on the aggressiveness of a patient’s prostate cancer, was classified as an “Advanced Tool” in the treatment of patients with prostate cancer.³

According to the NCCN guidelines for prostate cancer, advanced tools are those that have exhibited superior prognostic performance vs standard tools and/or assisted clinicians as a predictive biomarker that identifies patients who may differentially benefit from a specific therapy.⁴ A Molecular Diagnostic Services Program Recommendation supports the use of Prolaris following biopsy for patients with NCCN very-low–, low-risk, and favorable intermediate-risk prostate cancer who have 10 or more years of life expectancy, no prior therapy for prostate cancer, and eligibility to receive active surveillance or definitive therapy.

References

1. Myriad Genetics partners with PATHOMIQ to add artificial intelligence technology platform to its oncology portfolio. News release. Myriad Genetics, Inc. February 24, 2025. Accessed February 25, 2025. https://tinyurl.com/5bp2se3n
2. Nair SS, Muhammad H, Jain P, et al. A novel artificial intelligence-powered tool for precise risk stratification of prostate cancer progression in patients with clinical intermediate risk. Eur Urol. 2024;S0302-2838(24):02496-5. doi:10.1016/j.eururo.2024.07.013
3. NCCN prostate cancer guidelines reinforce status of Myriad Genetics' Prolaris® test as an 'Advanced Tool' recommended for prognostic assessment. News release. Myriad Genetics, Inc. December 9, 2024. Accessed February 25, 2025. https://tinyurl.com/yc8nc2cx
4. NCCN. Clinical Practice Guidelines in Oncology. Prostate cancer, version 1.2025. Accessed February 25, 2025. https://tinyurl.com/57yjccv6